We’re downgrading Lilly and asking ourselves tough questions after its obesity
Eli Lilly delivered strong second-quarter results on Thursday, but shares are…
Subscribe to our mailing list and get interesting stuff and updates to your email inbox.
Thank you for subscribing.
Something went wrong.